Advances in adjuvant systemic therapy for non-small-cell lung cancer

Table 2 Incidence of treatment-related World Health Organization grade 3-4 toxicity from adjuvant cisplatin and vinorelbine

Trial	JBR.10 (%)[16]	ANITA (%)[18]
Anaemia	14	7
Thrombocytopenia	3	1
Neutropenia	85	73
Febrile neutropenia	9	7
Infection	11	1
Nausea/vomiting	27	10-171
Diarrhoea	2	< 1
Constipation	5	3
Anorexia	15	10
Asthenia/fatigue	28	15
Peripheral neuropathy	3	3-72
Creatinine elevation	(NR)3	< 1
Treatment-related mortality4	0.8	2

¹Separately documented as nausea (10%) and vomiting (7%) in publication;

²Separately documented as hearing loss (2%), sensory neuropathy (2%) and motor neuropathy (3%) in publication;

³NR: Not reported;

⁴No WHO grade.